Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ROSACEA”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 289 records · Page 16Linked to original sources
PubMed2001

Isolation, characterization, and systematic significance of 2-pyrone-4,6-dicarboxylic acid in Rosaceae.

2-Pyrone-4,6-dicarboxylic acid was isolated from Potentilla anserina. Until now this substance was only found in bacteria and not in higher plants. By sterile cultivation it was verified that this compound is genuine also in plants. In addition the systematic relevance of 2-pyrone-4,6-dicarboxylic acid within the Rosaceae was tested. The compound seems to be a chemotaxonomic marker for the Rosoideae sensu stricto proposed by Morgan et al. (Morgan, D.R., Soltis, D.E., Robertson, K.R., 1994. Systematic and evolutionary implications of rbcL sequence variation in Rosaceae. American Journal of Botany 81, 890-903).

Chromatography, High Pressure Liquid↗
PubMed1976

Treatment of rosacea by metronidazole.

A double-blind trial in twenty-nine patients with rosacea showed that, after 6 weeks' treatment, metronidazole was therapeutically superior to a placebo (P less than 0-02). It was particularly effective against papules and pustules. The mode of action of metronidazole and other antibiotics in rosacea is not known.

Administration, Oral↗
PubMed2005

[Staphylococcal endophthalmitis following cataract surgery in a patient with ocular rosacea].

PURPOSE: To report staphylococcal endophthalmitis following cataract surgery in a patient with ocular rosacea. OBSERVATION: A 69-year-old man presented with decreased visual acuity in the right eye, a corneal abscess on the incision and hypopyon 2 weeks after phacoemulsification with intraocular lens placement. The patient was hospitalized. A diagnostic vitreous tap was performed. Antibiotic therapy was initiated both locally (two intravitreal shots + topical administration) and intravenously. RESULTS: Vitreal tap cultures indicated Staphylococcus aureus. The patient's clinical status improved 48 hours after the second intravitreal shot. The same bacterium was cultured from the patient's eyelids and incision abscess. Multilayer amniotic membrane transplantation enabled satisfactory healing of the corneal abscess, which had become perforative. CONCLUSIONS: The source of the S. aureus was the skin lesions on the patient's eyelids. Rosacea is a skin disease that frequently affects the face, nose and eyelids. Although good surgical techniques were performed, with the incision requiring suture, the risk of endophthalmitis after intraocular surgery was increased in the absence of proper preoperative treatment of the dermatological condition.

Aged↗
PubMed2004

Tacrolimus effect on rosacea.

Twenty-four patients with erythrotelangiectatic or papulopustular rosacea were treated with 0.1% tacrolimus topical ointment in a 12-week open-label trial. Erythema was significantly improved in both rosacea subtypes (P<.05). There was no decrease in the number of papulopustular lesions. Side effects were consistent with those on the tacrolimus topical ointment labeling.

Female↗
PubMed2001

Acne vulgaris and rosacea: evaluation and management.

Acne vulgaris, commonly termed acne, is an extremely common disease. It can be found in nearly all teenagers to some degree as well as in women in their 30s. Regardless of severity, acne often has a greater psychologic effect than cutaneous effect. Indeed, most patients overestimate the severity of their disease, while most physicians underestimate its impact on their patients. Studies have shown that people with severe acne as teens are less employable as adults and that self-esteem is low. When combined with other adolescent tensions, acne can be a difficult disease to treat. Rosacea, which usually starts in the late 20s, may affect the eyes as well as the skin. This article describes the pathogenesis of acne and rosacea and treatment approaches the primary care physician can use.

Acne Vulgaris↗
PubMed1992

Development of an orphan drug by a start-up company. MetroGel for rosacea.

The Orphan Drug Act of 1983, along with the discovery of a new use for a known drug and an investor willing to assume the necessary risk, brought about the formation of a start-up pharmaceutical company. The primary incentive of the Orphan Drug Act of seven years of marketing exclusivity provided the protection from competition necessary for recovery of the significant research and development and marketing costs. The orphan product, MetroGel, for the treatment of rosacea, required approximately five years of development before it was approved for marketing by the Food and Drug Administration. MetroGel has become the number one drug in the United States for the treatment of rosacea. It currently is marketed in other countries through a licensing agreement with a major pharmaceutical company.

Administration, Topical↗
PubMed2004

Use of the KTP laser in the treatment of rosacea and solar lentigines.

Numerous techniques have evolved in facial plastic surgery to treat rosacea and solar lentigines. The treatment regimens range from avoidance of causative factors to the use of topical agents or other modalities that target the superficial layers of the skin. Of the modalities that target the epidermis, lasers offer the physician and patient the ability to target specific chromophores in the skin. Advances in laser technology led to the implementation of targeting certain characteristic pigments of abnormal areas with minimal damage to surrounding normal tissue. Rosacea and solar lentigines have characteristic cells that are targeted by a potassium-titanyl-phosphate (KTP) laser. The lesions are different in their origins but share the ability to be treated successfully with the KTP laser. A review of both conditions and other treatment options is discussed.

Facial Dermatoses↗
PubMed2006

[Repair of an extensive corneoscleral perforation in a case of ocular rosacea with a keratoplasty].

BACKGROUND: A 58-year-old female patient with rosacea and a 7year history of eye trouble presented with a spontaneous corneoscleral perforation of the left eye. METHODS: The persisting ocular hypotonia with retinal folds made a closure of the leakage area necessary. Covering with a corneal transplant was chosen from among several possibilities available for the repair of eye-surface defects. The involved parts of the sclera and cornea were removed in a diameter of 7 mm. RESULTS AND CONCLUSIONS: The almost 6-year postoperative course with virtually no problems confirmed the keratoplasty as being effective therapy also in the case of perforation in rosacea scleroperikeratitis.

Corneal Transplantation↗
PubMed2001

Identifying and treating rosacea.

Rosacea is a chronic, cutaneous vascular disorder that affects approximately 13 million Americans. The facial disorder, which often affects people of Northern European descent, is characterized by four stages. Although rosacea is not curable, early recognition and treatment can prevent progression to permanent disfigurement or blindness. Pharmacologic therapy, patient education, and symptom management can provide symptom control and remission.

Anti-Bacterial Agents↗
PubMed1989

Steroid-withdrawal rosacea-like dermatitis.

A patient with malignant lymphoma repeatedly developed transient rosacea-like dermatitis several days after each interruption of continuous oral prednisone intake. We thought that the eruption was provoked by withdrawal of orally administered steroid, and thus we diagnosed the patient as having steroid-withdrawal rosacea-like dermatitis, one manifestation of steroid-withdrawal syndrome.

Adult↗
PubMed1993

Folliculosebaceous cystic hamartoma associated with rosacea.

A case of folliculosebaceous cystic hamartoma associated with rosacea is presented. Clinically, a solid, 5-mm-sized nodule was observed on the nose which showed telangiectasia and a waxy appearance. Histologically, a large horn cyst was located in the dermis, and was continuous with the surface epidermis. It was associated with mature sebaceous glands and immature hair follicles. Folliculosebaceous cystic hamartoma and similar cases have recently been reported, but this is the first report accompanied by rosacea.

Cysts↗
PubMed1976

Skin surface lipid composition in rosacea.

Skin surface lipid composition was measured in thirty-one patients with rosacea and their age-matched controls. Patients with rosacea had normal lipid composition, and there was no correlation between the lipid composition and the severity of the disease. Tetracycline therapy produced no measurable change in lipid composition.

Adult↗
PubMed1980

A double-blind trial of metronidazole versus oxytetracycline therapy for rosacea.

Forty patients with papulo-pustular rosacea were treated for 12 weeks on a random double-blind basis either with oxytetracycline 250 mg twice daily or with metronidazole 200 mg twice daily. Both drugs produced an improvement which was greater after 12 weeks than after 6 weeks, but there was no significant difference between them. Metronidazole appears to be a safe and effective drug for the treatment of rosacea.

Clinical Trials as Topic↗
PubMed1986

Anti-oxidant action of metronidazole: a possible mechanism of action in rosacea.

To elucidate the mechanism of action of metronidazole in the treatment of rosacea, the effect of metronidazole on the generation of reactive oxygen species was examined both in neutrophil and xanthine-xanthine oxidase systems. Metronidazole had anti-oxidant action which was not exerted by the scavenging of reactive oxygen species, but by having an effect on neutrophil cell functions. Beneficial effects of metronidazole in the treatment of papulopustular rosacea can in part be attributable to this anti-inflammatory effect.

Cells, Cultured↗
PubMed2004

Rosacea fulminans in pregnancy.

Rosacea fulminans is a rare condition with a female preponderance and unknown aetiology, characterized by the abrupt onset of papules, pustules and erythema affecting the face. Corticosteroids and isotretinoin are regarded as the two main therapeutic agents. We report a case associated with pregnancy, and discuss the therapeutic implications. This is the first published report of rosacea fulminans in pregnancy complicated by stillbirth.

Adult↗
PubMed1986

Treatment of rosacea with isotretinoin.

A multicenter trial of isotretinoin in severe papulopustular rosacea in adult patients was undertaken to evaluate the efficacy and safety of this treatment. A 20-week course of therapy was instituted in 92 patients from 11 dermatology departments. At the end of the study period, isotretinoin was found to be highly effective in the clearing of refractory rosacea lesions.

Administration, Oral↗
PubMed2002

Laser treatment of rosacea.

Rosacea is a common condition often resulting in persistent erythema and telangiectasia as well as rhinophyma in a number of patients. Over the last two decades lasers have been increasingly used in the treatment of these permanent changes. The literature is reviewed in terms of the different laser systems, side-effects and comparison with other surgical techniques. Laser studies on rosacea-associated telangiectasia and erythema are limited. Copper-bromide, krypton and KTP lasers have been used with good to excellent results. However, the most commonly applied system is the flash lamp-pumped pulsed dye laser. Rhinophyma can be treated with a variety of different surgical methods, including laser resurfacing. CO(2) lasers are the most widely used lasers, others are the Er:YAG and Nd:YAG lasers. Cosmetic end results are comparable to partial excision with a scalpel or electrosurgery. There does not appear to be an increased risk of infection or scarring, but the conventional surgical methods are quicker to perform and more cost effective.

Humans↗
PubMed1982

Oxytetracycline in the treatment of ocular rosacea: a double-blind trial.

Thirty-five patients with ocular rosacea were admitted to a trial of systemic oxytetracycline, 250 mg b.d. for 6 weeks. Oxytetracycline produced a significantly higher number of remissions than the placebo, 11/35. With repeated or continuous treatment 19/35 patients achieved a sustained remission for 8 months. There were no side effects. The nonspecific signs of ocular rosacea responded well to the treatment, but no permanent change in the conjunctival or corneal vascularisation occurred.

Clinical Trials as Topic↗